<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="179">
  <stage>Registered</stage>
  <submitdate>11/08/2005</submitdate>
  <approvaldate>2/09/2005</approvaldate>
  <actrnumber>ACTRN12605000269639</actrnumber>
  <trial_identification>
    <studytitle>The effect of varying remifentanil infusion rates on target controlled infusion propofol concentrations necessary to maintain anaesthesia as assessed by bi-spectral index</studytitle>
    <scientifictitle>The effect of varying remifentanil infusion rates on target controlled infusion propofol concentrations necessary to maintain anaesthesia as assessed by bi-spectral index</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Anaesthesia</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Remifentanil and propofol at induction of anaesthesia.</interventions>
    <comparator>nil</comparator>
    <control>Dose comparison</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose of remifentanil and propofol required to maintain bi-spectral index &lt; 50</outcome>
      <timepoint>30 minutes</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>NIL</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Surgery under general anaesthesia.</inclusivecriteria>
    <inclusiveminage>25</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant and breastfeeding women, severe ischaemic heart disease, severe hypovolaemia, allergy to propofol or egg, emergency surgery, current opioid, benzodiazepine or high alcohol use.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed envelopes</concealment>
    <sequence>up-down sequential allocation with pool of 12 for each remifentanil infusion rate</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures>Up - down sequential allocation</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>10/12/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>72</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6000</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Lars Wang</primarysponsorname>
    <primarysponsoraddress>Department of Anaesthesia and Pain Medicine, Royal Perth Hospital, Wellington St, Perth WA 6000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Perth Hospital</sponsorname>
      <sponsoraddress>Wellington St Perth WA 6000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress>Wellington St, Perth WA 6000</ethicaddress>
      <ethicapprovaldate>1/09/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Shauna Fatovich</name>
      <address>Department of Anaesthesia and Pain Medicine
Royal Perth Hospital
Wellington Street
Perth WA 6000</address>
      <phone>+61 8 92241036</phone>
      <fax />
      <email>shauna.fatovich@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lars Wang</name>
      <address>Department of Anaesthesia and Pain Medicine
Royal Perth Hospital
Wellington Street
Perth WA 6000</address>
      <phone>+61 8 92241034</phone>
      <fax />
      <email>lars.wang@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>